Interpretation of the evidence for the efficacy and safety of statin therapy
Open accessAbstract
This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect a failure to recognise the limitations of other sources of evidence about the effects of treatment. Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction in LDL cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend on an individual's absolute risk of occlusive vascular events and the absolute reduction in LDL cholesterol that is achieved. For example, lowering LDL cholesterol by 2 mmol/L (77 mg/dL) with an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about £2 per month) for 5 years in 10 000 patients would typically prevent major vascular events from occurring in about 1000 patients (ie, 10% absolute benefit) with pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% absolute benefit) who are at increased risk but have not yet had a vascular event (primary prevention). Statin therapy has been shown to reduce vascular disease risk during each year it continues to be taken, so larger absolute benefits would accrue with more prolonged therapy, and these benefits persist long term. The only serious adverse events that have been shown to be caused by long-term statin therapy-ie, adverse effects of the statin-are myopathy (defined as muscle pain or weakness combined with large increases in blood concentrations of creatine kinase), new-onset diabetes mellitus, and, probably, haemorrhagic stroke. Typically, treatment of 10 000 patients for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of myopathy (one of which might progress, if the statin therapy is not stopped, to the more severe condition of rhabdomyolysis), 50-100 new cases of diabetes, and 5-10 haemorrhagic strokes. However, any adverse impact of these side-effects on major vascular events has already been taken into account in the estimates of the absolute benefits. Statin therapy may cause symptomatic adverse events (eg, muscle pain or weakness) in up to about 50-100 patients (ie, 0·5-1·0% absolute harm) per 10 000 treated for 5 years. However, placebo-controlled randomised trials have shown definitively that almost all of the symptomatic adverse events that are attributed to statin therapy in routine practice are not actually caused by it (ie, they represent misattribution). The large-scale evidence available from randomised trials also indicates that it is unlikely that large absolute excesses in other serious adverse events still await discovery. Consequently, any further findings that emerge about the effects of statin therapy would not be expected to alter materially the balance of benefits and harms. It is, therefore, of concern that exaggerated claims about side-effect rates with statin therapy may be responsible for its under-use among individuals at increased risk of cardiovascular events. For, whereas the rare cases of myopathy and any muscle-related symptoms that are attributed to statin therapy generally resolve rapidly when treatment is stopped, the heart attacks or strokes that may occur if statin therapy is stopped unnecessarily can be devastating.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
LDL-lowering drugs have only moderate effects on triglyceride levels.
“Although LDL-lowering drugs have only moderate effects on TG levels, they reduce ASCVD risk in patients with and without HTG.42”
From Clinical review on triglycerides (2020) · cites this paper as [42]
LDL-lowering drugs reduce ASCVD risk in patients with and without hypertriglyceridaemia.
“Although LDL-lowering drugs have only moderate effects on TG levels, they reduce ASCVD risk in patients with and without HTG.42”
From Clinical review on triglycerides (2020) · cites this paper as [42]
Overall, statin therapy produced a 21% relative reduction in major vascular events (relative risk 0.79, 95% CI 0.77-0.81) per 1.0 mmol/L LDL-C reduction.
“Overall, statin therapy produced a 21% relative reduction in major vascular events (relative risk 0.79, 95% CI 0.77-0.81) per 1.0 mmoL/L reduction in LDL-C”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
Because absolute coronary artery disease risk is higher in older persons, the absolute increase in risk for a given increment in total cholesterol is larger with increasing age.
“However, since the absolute risk of CAD is higher in older persons, the associated absolute increase in risk for a given increment in TC is larger with increasing age [217].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
The relative reduction in major vascular events was similar irrespective of age among patients with pre-existing vascular disease, but appeared smaller among older individuals without known vascular disease.
“The relative reduction in major vascular events was similar, irrespective of age, among patients with pre-existing vascular disease, but appeared smaller among older individuals not known to have vascular disease.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Reduced dietary salt for the prevention of cardiovascular disease
Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L., & Ebrahim, S. B. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009217.pub2 · Cited by 311 · see citing works
RetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · see citing works
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · see citing works
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848 · see citing works
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · see citing works
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550 · see citing works
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216 · see citing works
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125 · see citing works
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677 · see citing works
Self-citationSever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,757 · see citing works
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641 · see citing works
Self-citationA Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease
Boushey, C. J. (1995) · JAMA · doi:10.1001/jama.1995.03530130055028 · Cited by 3,604 · see citing works
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378 · see citing works
Breast cancer and hormone-replacement therapy in the Million Women Study
Beral, V. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,986 · see citing works
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907 · see citing works
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887 · see citing works
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833 · see citing works
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761 · see citing works
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731 · see citing works
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544 · see citing works
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436 · see citing works
Self-citationData Resource Profile: The Survey of Health, Ageing and Retirement in Europe (SHARE)
Borsch-Supan, A. H., Brandt, M., Hunkler, C., Kneip, T., Korbmacher, J. M., Malter, F., Schaan, B., Stuck, S., & Zuber, S. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt088 · Cited by 2,398 · see citing works
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D. M., Ettinger, B. B., Ernster, V. L., & Cummings, S. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-1016 · Cited by 2,329 · see citing works
Systematic Review and Meta-analysis
Garg, A. X., Hackam, D. G., & Tonelli, M. A. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01430307 · Cited by 2,252 · see citing works
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · see citing works
<i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · see citing works
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934 · see citing works
Self-citationCardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
Grady, D. G., Herrington, D. M., Bittner, V., Blumenthal, R. S., Davidson, M., Hlatky, M. A., Hsia, J. A., Hulley, S. B., Herd, A. J., Khan, S. S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,926 · see citing works
Self-citationLaw, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720 · see citing works
Self-citationEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · see citing works
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., et al. (2013) · JAMA · doi:10.1001/jama.2013.278040 · Cited by 1,650 · see citing works
Stampfer, M. J., & Colditz, G. A. (1991) · Preventive Medicine · doi:10.1016/0091-7435(91)90006-p · Cited by 1,611 · see citing works
Why we need observational studies to evaluate the effectiveness of health care
Black, N. (1996) · BMJ · doi:10.1136/bmj.312.7040.1215 · Cited by 1,598 · see citing works
Bias and causal associations in observational research
Grimes, D. A., & Schulz, K. F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07451-2 · Cited by 1,553 · see citing works
Self-citationStroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443 · see citing works
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390 · see citing works
Self-citationLaw, M., Wald, N., & Thompson, S. (1994) · British medical journal · doi:10.1136/bmj.308.6925.367 · Cited by 1,306 · see citing works
Self-citationA review of uses of health care utilization databases for epidemiologic research on therapeutics
Schneeweiß, S., & Avorn, J. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.012 · Cited by 1,290 · see citing works
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226 · see citing works
Subgroup analysis and other (mis)uses of baseline data in clinical trials
Assmann, S. F., Pocock, S. J., Enos, L. E., & Kasten, L. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02039-0 · Cited by 1,167 · see citing works
Iso, H., Jacobs, D. R., Wentworth, D. N., Neaton, J. D., & Cohen, J. D. (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201405 · Cited by 1,130 · see citing works
Aspirin and the Risk of Colorectal Cancer in Women
Giovannucci, E. L., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331001 · Cited by 1,095 · see citing works
Vivekananthan, D. P., Penn, M. S., Sapp, S. K., Hsu, A., & Topol, E. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13637-9 · Cited by 1,083 · see citing works
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057 · see citing works
Collins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15690-0 · Cited by 1,055 · see citing works
Self-citationStatin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030 · see citing works
Yusuf, S. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470010097038 · Cited by 1,014 · see citing works
Self-citation<i>Meta-analysis</i> Spurious precision? Meta-analysis of observational studies
Egger, M., Schneider, M., & Smith, G. D. (1998) · BMJ · doi:10.1136/bmj.316.7125.140 · Cited by 997 · see citing works
Self-citationYusuf, S., Islam, S., Chow, C. K., Rangarajan, S., Dagenais, G., Diaz, R., Gupta, R., Kelishadi, R., Iqbal, R., Avezum, A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61215-4 · Cited by 964 · see citing works
Self-citationMuldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960 · see citing works
Blinding in randomised trials: hiding who got what
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07816-9 · Cited by 952 · see citing works
Self-citationFerence, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.017 · Cited by 898 · see citing works
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 878 · see citing works
Why Representativeness Should Be Avoided
Rothman, K. J., Gallacher, J. E., & Hatch, E. E. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dys223 · Cited by 861 · see citing works
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848 · see citing works
Self-citationThe safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833 · see citing works
Self-citationObservational Studies Analyzed Like Randomized Experiments
Hernán, M. Á., Alonso, Á., Logan, R. W., Grodstein, F., Michels, K. B., Willett, W. C., Manson, J. E., & Robins, J. M. (2008) · Epidemiology · doi:10.1097/ede.0b013e3181875e61 · Cited by 822 · see citing works
McCarey, D. W., McInnes, I. B., Madhok, R., Hampson, R., Scherbakova, O., Ford, I., Capell, H. A., & Sattar, N. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16449-0 · Cited by 818 · see citing works
Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816 · see citing works
Self-citationStatin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808 · see citing works
Self-citationStatins and the Risk of Colorectal Cancer
Poynter, J. N., Gruber, S. B., Higgins, P., Almog, R., Bonner, J. D., Rennert, H. S., Low, M., Greenson, J. K., & Rennert, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043792 · Cited by 806 · see citing works
Nonspecific medication side effects and the nocebo phenomenon
Barsky, A. J. (2002) · JAMA · doi:10.1001/jama.287.5.622 · Cited by 784 · see citing works
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
Glynn, R. J., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900241 · Cited by 748 · see citing works
Self-citationThe Impact of Residual and Unmeasured Confounding in Epidemiologic Studies: A Simulation Study
Fewell, Z., Davey Smith, G., & Sterne, J. A. C. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm165 · Cited by 734 · see citing works
Self-citationStatin Use and Reduced Cancer-Related Mortality
Klop, C., Driessen, J. H. M., & de Vries, F. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1214827 · Cited by 722 · see citing works
Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61183-1 · Cited by 680 · see citing works
Self-citationHPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676 · see citing works
Self-citationUse of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O. H. Y., Eberg, M., Benayoun, S., Aprikian, A. G., Batist, G., Suissa, S., & Azoulay, L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 661 · see citing works
Problems in the “Evidence” of “Evidence-Based Medicine”
Feinstein, A. R., & Horwitz, R. I. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00244-1 · Cited by 653 · see citing works
<i>Meta-analysis:</i> Potentials and promise
Egger, M., & Smith, G. D. (1997) · BMJ · doi:10.1136/bmj.315.7119.1371 · Cited by 646 · see citing works
Self-citationJBS3 Board (2014) · Heart · doi:10.1136/heartjnl-2014-305693 · Cited by 608 · see citing works
When are randomised trials unnecessary? Picking signal from noise
Glasziou, P., Chalmers, I., Rawlins, M. D., & McCulloch, P. G. (2007) · BMJ · doi:10.1136/bmj.39070.527986.68 · Cited by 585 · see citing works
Hulley, S. B. (2002) · JAMA · Cited by 577 · see citing works
Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives -
Zhou, Q., & Liao, J. K. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0110 · Cited by 566 · see citing works
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558 · cited 3× · see citing works
“in combination with certain antihypertensive drugs and in women, people aged over 80, and those with diabetes).(78)”
BackgroundRandomized Trials or Observational Tribulations?
Pocock, S. J., & Elbourne, D. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422511 · Cited by 550 · see citing works
Discontinuation of Statins in Routine Care Settings: A Cohort Study
Zhang, H., Plutzky, J., Skentzos, S., Morrison, F., Mar, P., Shubina, M., & Turchin, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00004 · Cited by 548 · see citing works
When are observational studies as credible as randomised trials?
Vandenbroucke, J. P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16261-2 · Cited by 538 · see citing works
Chen, Z., Peto, R., Collins, R., MacMahon, S. W., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537 · see citing works
Self-citationRosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome
The National Heart, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401520 · Cited by 533 · see citing works
Trends in Serum Lipids and Lipoproteins of Adults, 1960-2002
Carroll, M. D. (2005) · JAMA · doi:10.1001/jama.294.14.1773 · Cited by 529 · see citing works
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Zadelaar, S., Kleemann, R., Verschuren, L., der Weij, J. D. V.-V., van der Hoorn, J., Princen, H. M. G., & Kooistra, T. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.142570 · Cited by 526 · see citing works
The Risk of Cancer in Users of Statins
Graaf, M. R., Beiderbeck, A. B., Egberts, T. C. G., Richel, D. J., & Guchelaar, H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.027 · Cited by 524 · see citing works
Nissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.3608 · Cited by 522 · see citing works
Self-citationHippisley‐Cox, J., & Coupland, C. A. C. (2010) · BMJ · doi:10.1136/bmj.c2197 · Cited by 511 · see citing works
Effect of statins on skeletal muscle function
Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.136101 · Cited by 500 · see citing works
(2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.348 · Cited by 498 · see citing works
Self-citationStatistics Notes: Blinding in clinical trials and other studies
Day, S. J. (2000) · BMJ · doi:10.1136/bmj.321.7259.504 · Cited by 487 · see citing works
An assessment by the statin muscle safety task force: 2014 update
Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., & Parker, B. A. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.03.004 · Cited by 485 · see citing works
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006) · Circulation · doi:10.1161/circulationaha.106.624890 · Cited by 474 · see citing works
Mohler, E. R., Hiatt, W. R., & Creager, M. A. (2003) · Circulation · doi:10.1161/01.cir.0000090686.57897.f5 · Cited by 473 · see citing works
Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.006 · Cited by 470 · see citing works
Simvastatin in the Acute Respiratory Distress Syndrome
McAuley, D. F., Laffey, J. G., O’Kane, C. M., Perkins, G. D., Mullan, B. A., Trinder, T. J., Johnston, P., Hopkins, P. A., Johnston, A. J., McDowell, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403285 · Cited by 466 · see citing works
Epidemiology of stroke and its subtypes in Chinese vs white populations
Tsai, C., Thomas, B. M., & Sudlow, C. L. M. (2013) · Neurology · doi:10.1212/wnl.0b013e31829bfde3 · Cited by 464 · see citing works
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative
Culver, A. L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.625 · Cited by 444 · see citing works
Randomisation to protect against selection bias in healthcare trials
Odgaard-Jensen, J., Vist, G. E., Timmer, A., Kunz, R., Akl, E. A., Schünemann, H., Briel, M., Nordmann, A. J., Pregno, S., & Oxman, A. D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000012.pub3 · Cited by 439 · see citing works
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438 · see citing works
Lawlor, D. A., Smith, G. D., Bruckdorfer, K. R., Kundu, D., & Ebrahim, S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16260-0 · Cited by 438 · see citing works
Self-citationHormone Replacement Therapy and Cardiovascular Disease
Mosca, L. J., Collins, P. D., Herrington, D. M., Mendelsohn, M. E., Pasternak, R. C., Robertson, R. M., Schenck-Gustafsson, K. G., Smith, S. C., Taubert, K. A., & WENGER, N. K. (2001) · Circulation · doi:10.1161/hc2901.092200 · Cited by 437 · see citing works
Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., Maxwell, W. D., McLeod, H. L., Krauss, R. M., Roden, D. M., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.125 · Cited by 434 · see citing works
McKenney, J. M., Davidson, M. H., Jacobson, T. A., & Guyton, J. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.02.030 · Cited by 431 · see citing works
Schatz, I. J., Masaki, K., Yano, K., Chen, R., Rodríguez, B. L., & Curb, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05553-2 · Cited by 425 · see citing works
Observational research, randomised trials, and two views of medical science
Vandenbroucke, J. P. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050067 · Cited by 416 · see citing works
Bosco, J. L. F., Silliman, R. A., Thwin, S. S., Geiger, A. M., Buist, D. S. M., Prout, M. N., Yood, M. U., Haque, R., Wei, F., & Lash, T. L. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.03.001 · Cited by 394 · see citing works
Credibility of claims of subgroup effects in randomised controlled trials: systematic review
Sun, X., Briel, M., Busse, J. W., You, J. J., Akl, E. A., Mejza, F., Bała, M. M., Bassler, D., Mertz, D., Diaz-Granados, N., et al. (2012) · BMJ · doi:10.1136/bmj.e1553 · Cited by 394 · see citing works
Confounding Control in Healthcare Database Research
Brookhart, M. A., Stürmer, T., Glynn, R. J., Rassen, J. A., & Schneeweiß, S. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181dbebe3 · Cited by 390 · see citing works
Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus
Besseling, J., Kastelein, J. J. P., Defesche, J. C., Hutten, B. A., & Hovingh, G. K. (2015) · JAMA · doi:10.1001/jama.2015.1206 · Cited by 387 · see citing works
Cholesterol, coronary heart disease, and stroke in the Asia Pacific region.
Asia Pacific Cohort Studies Collaboration (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg106 · Cited by 382 · see citing works
Heart Protection Study Collaborative Group (2011) · The Lancet · doi:10.1016/s0140-6736(11)61125-2 · Cited by 373 · see citing works
Statistics notes. Treatment allocation in controlled trials: why randomise?
Altman, D. G., & Bland, J. M. (1999) · BMJ · doi:10.1136/bmj.318.7192.1209 · Cited by 362 · see citing works
De testimonio: on the evidence for decisions about the use of therapeutic interventions
Rawlins, M. D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61930-3 · Cited by 362 · see citing works
Should there be a moratorium on the use of cholesterol lowering drugs?
Smith, G. D., & Pekkanen, J. (1992) · British medical journal · doi:10.1136/bmj.304.6824.431 · Cited by 357 · see citing works
Self-citationAn Assessment of Statin Safety by Hepatologists
Cohen, D. E., Anania, F. A., & Chalasani, N. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.014 · Cited by 354 · see citing works
Cholesterol Treatment Trialists' (CTT) Collaboration (2012) · PLoS ONE · doi:10.1371/journal.pone.0029849 · Cited by 351 · see citing works
Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD
Criner, G. J., Connett, J. E., Aaron, S. D., Albert, R. K., Bailey, W. C., Casaburi, R. H., Cooper, J. A. D., Curtis, J. L., Dransfield, M. T., Han, M. K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403086 · Cited by 347 · see citing works
Ravnskov, U., Diamond, D. M., Hama, R., Hamazaki, T., Hammarskjöld, B., Hynes, N., Kendrick, M. E., Langsjoen, P. H., Malhotra, A., Mascitelli, L., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010401 · Cited by 346 · see citing works
Holdaas, H., Fellström, B., Cole, E., Nyberg, G., OLSSON, A. G., Pedersen, T. R., Madsen, S., Grönhagen‐Riska, C., Neumayer, H. ‐., Maes, B., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01105.x · Cited by 343 · see citing works
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30156-5 · Cited by 338 · see citing works
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials
Collins, R., & MacMahon, S. W. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03651-5 · Cited by 337 · see citing works
Self-citationA randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., & Aisen, P. S. S. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bf11 · Cited by 337 · see citing works
Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin
Waters, D. D., Ho, J. E., DeMicco, D. A., Breazna, A., Arsenault, B. J., Wun, C.-C., Kastelein, J. J., Colhoun, H., & Barter, P. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.047 · Cited by 333 · see citing works
Strandberg, T. E., Pyörälà, K., Cook, T. J., Wilhelmsen, L., Færgeman, O., Þorgeirsson, G., Pedersen, T. R., & KJEKSHUS, J. K. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 330 · see citing works
Nielsen, S. F., & Nordestgaard, B. G. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv641 · Cited by 329 · see citing works
Perioperative Rosuvastatin in Cardiac Surgery
Zheng, Z., Jayaram, R., Jiang, L., Emberson, J., Zhao, Y., Li, Q., Du, J., Guarguagli, S., Hill, M., Chen, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507750 · Cited by 322 · see citing works
Self-citationHepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing
Bjornsson, E. S., Jacobsen, E. I., & Kalaitzakis, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.023 · Cited by 320 · see citing works
Cholesterol lowering trials in coronary heart disease: Frequency of citation and outcome.
Ravnskov, U. (1992) · BMJ · doi:10.1136/bmj.305.6844.15 · Cited by 313 · see citing works
Assessing possible hazards of reducing serum cholesterol
Law, M. R., Thompson, S. G., & Wald, N. (1994) · BMJ · doi:10.1136/bmj.308.6925.373 · Cited by 312 · see citing works
Self-citationNumbers needed to treat derived from meta-analyses---sometimes informative, usually misleading
Smeeth, L. L., Haines, A., & Ebrahim, S. B. J. (1999) · BMJ · doi:10.1136/bmj.318.7197.1548 · Cited by 301 · see citing works
Self-citationAssociation of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes
White, J., Swerdlow, D. I., Preiss, D., Fairhurst-Hunter, Z., Keating, B. J., Asselbergs, F. W., Sattar, N., Humphries, S. E., Hingorani, A. D., & Holmes, M. V. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1884 · Cited by 293 · see citing works
Self-citationNaci, H., Brugts, J., & Ades, T. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000071 · Cited by 292 · see citing works
Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291 · see citing works
Pedersen, T. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440170097011 · Cited by 283 · see citing works
Trends in Lipids and Lipoproteins in US Adults, 1988-2010
Carroll, M. D., Kit, B. K., Lacher, D. A., Shero, S. T., & Mussolino, M. E. (2012) · JAMA · doi:10.1001/jama.2012.13260 · Cited by 282 · see citing works
Phillips, A. N., & Smith, G. D. (1991) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(91)90155-3 · Cited by 275 · see citing works
Self-citationKnatterud, G. L., Rosenberg, Y., CAMPEAU, L. A., Geller, N. L., Hunninghake, D. B., Forman, S. A., Forrester, J. S., Gobel, F. L., Herd, J. A., Hickey, A., et al. (2000) · Circulation · doi:10.1161/01.cir.102.2.157 · Cited by 273 · see citing works
Drug Treatment of Hyperlipidemia in Women
Walsh, J. M. E. (2004) · JAMA · doi:10.1001/jama.291.18.2243 · Cited by 270 · see citing works
Statins and risk of polyneuropathy
Gaist, D., Jeppesen, U., Andersen, M. T., Rodríguez, L. A. G., Hallas, J., & Sindrup, S. H. (2002) · Neurology · doi:10.1212/wnl.58.9.1333 · Cited by 270 · see citing works
Prentice, R. L., Langer, R., Stefanick, M. L., Howard, B. V., Pettinger, M. B., Anderson, G. L., Barad, D. H., Curb, J. D., Kotchen, J. M., Kuller, L. H., et al. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi223 · Cited by 261 · see citing works
False Alarms and Pseudo-Epidemics: The Limitations of Observational Epidemiology
Grimes, D. A., & Schulz, K. F. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31826af61a · Cited by 254 · see citing works
Self-citationA systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253 · see citing works
Beyond the Randomized Clinical Trial
Nallamothu, B. K., Hayward, R. A., & Bates, E. (2008) · Circulation · doi:10.1161/circulationaha.107.703579 · Cited by 251 · see citing works
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250 · see citing works
MacMahon, S. W., & Collins, R. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04017-4 · Cited by 249 · see citing works
Self-citationDormuth, C. R., Hemmelgarn, B. R., Paterson, J. M., James, M. T., Teare, G. F., Raymond, C. B., Lafrance, J., Levy, A. R., Garg, A. X., Ernst, P., et al. (2013) · BMJ · doi:10.1136/bmj.f880 · Cited by 248 · see citing works
Ford, I., Murray, H., McCowan, C., & Packard, C. J. (2016) · Circulation · doi:10.1161/circulationaha.115.019014 · Cited by 238 · see citing works
High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery
Billings, F. T., Hendricks, P. A., Schildcrout, J. S., Shi, Y., Petracek, M. R., Byrne, J. G., & Brown, N. J. (2016) · JAMA · doi:10.1001/jama.2016.0548 · Cited by 237 · see citing works
Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause
Prentice, R. L., Manson, J. E., Langer, R. D., Anderson, G. L., Pettinger, M. B., Jackson, R. D., Johnson, K., Kuller, L. H., Lane, D. S., Wactawski‐Wende, J., et al. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp115 · Cited by 234 · see citing works
Swiger, K. J., Manalac, R. J., Blumenthal, R. S., Blaha, M. J., & Martin, S. S. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.07.013 · Cited by 232 · see citing works
Self-citationHsia, J., MacFadyen, J. G., Monyak, J., & Ridker, P. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.082 · Cited by 231 · see citing works
Self-citationMatthews, A., Herrett, E., Gasparrini, A., Van Staa, T., Goldacre, B., Smeeth, L., & Bhaskaran, K. (2016) · BMJ · doi:10.1136/bmj.i3283 · Cited by 221 · see citing works
Self-citationDe Testimonio: on the evidence for decisions about the use of therapeutic interventions
Rawlins, M. D. (2008) · Clinical Medicine · doi:10.7861/clinmedicine.8-6-579 · Cited by 219 · see citing works
Statin myopathy: A common dilemma not reflected in clinical trials
Fernandez, G., Spatz, E. S., Jablecki, C. K., & Phillips, P. S. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10073 · Cited by 216 · see citing works
Finegold, J. A., Manisty, C. H., Goldacre, B., Barron, A. J., & Francis, D. P. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314525531 · Cited by 214 · see citing works
Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone
Chlebowski, R. T., Rohan, T. E., Manson, J. E., Aragaki, A. K., Kaunitz, A. M., Stefanick, M. L., Simon, M. S., Johnson, K., Wactawski‐Wende, J., O’Sullivan, M. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0494 · Cited by 210 · see citing works
Should people at low risk of cardiovascular disease take a statin?
Abramson, J. D., Rosenberg, H. G., Jewell, N., & Wright, J. M. (2013) · BMJ · doi:10.1136/bmj.f6123 · Cited by 208 · see citing works
Limits of observational data in determining outcomes from cancer therapy
Giordano, S. H., Kuo, Y., Duan, Z., Hortobágyi, G. N., Freeman, J. L., & Goodwin, J. S. (2008) · Cancer · doi:10.1002/cncr.23452 · Cited by 205 · see citing works
Anand, S. S. (2003) · Vascular Medicine · doi:10.1191/1358863x03vm518xx · Cited by 201 · see citing works
A randomized trial of Coenzyme Q10 in patients with confirmed statin myopathy
Taylor, B. A., Lorson, L., White, C. M., & Thompson, P. D. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.016 · Cited by 200 · see citing works
Moneta, G. L. (2006) · Yearbook of Vascular Surgery · doi:10.1016/s0749-4041(08)70219-7 · Cited by 200 · see citing works
The nocebo effect: patient expectations and medication side effects
Faasse, K., & Petrie, K. J. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-131730 · Cited by 191 · see citing works
Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis.
Gutierrez, J., Ramirez, G., Rundek, T., & Sacco, R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.2145 · Cited by 188 · see citing works
Rapid regression of atherosclerosis: insights from the clinical and experimental literature
Williams, K. J., Feig, J. E., & Fisher, E. A. A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1086 · Cited by 188 · see citing works
Randomisation to protect against selection bias in healthcare trials
Kunz, R., Vist, G. E., & Oxman, A. D. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000012.pub2 · Cited by 188 · see citing works
Ebrahim, S. B. J., Sung, J., Song, Y., Ferrer, R. L., Lawlor, D. A., & Smith, G. D. (2006) · BMJ · doi:10.1136/bmj.38855.610324.80 · Cited by 187 · see citing works
Self-citationO’Neal, H. R., Koyama, T., Koehler, E., Siew, E. D., Curtis, B. R., Fremont, R. D., May, A. K., Bernard, G. R., & Ware, L. B. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e3182120992 · Cited by 185 · see citing works
Macedo, A. F., Taylor, F. C., Casas, J. P., Adler, A. J., Prieto‐Merino, D., & Ebrahim, S. B. J. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-51 · Cited by 183 · see citing works
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA · doi:10.1001/jama.2012.8439 · Cited by 181 · see citing works
Self-citationCollins, R., Gray, R. G., Godwin, J., & Peto, R. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060308 · Cited by 178 · see citing works
Self-citationPrior Statin Use Is Associated with Improved Outcomes in Community-acquired Pneumonia
Chalmers, J. D., Singanayagam, A., Murray, M., & Hill, A. T. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.06.030 · Cited by 176 · see citing works
Effects of Lowering LDL Cholesterol on Progression of Kidney Disease
Haynes, R., Lewis, D., Emberson, J., Reith, C. A., Agodoa, L. Y. C., Cass, A., Craig, J. C., de Zeeuw, D., Feldt‐Rasmussen, B., Fellström, B., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013090965 · Cited by 176 · see citing works
Self-citationNon-cardiovascular effects associated with statins
Desai, C. S., Martin, S. S., & Blumenthal, R. S. (2014) · BMJ · doi:10.1136/bmj.g3743 · Cited by 172 · see citing works
Self-citationImpact of statins and ACE inhibitors on mortality after COPD exacerbations
Mortensen, E. M., Copeland, L. A., Pugh, M. J., Restrepo, M. I., de Molina, R. M., Nakashima, B., & Anzueto, A. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-45 · Cited by 170 · see citing works
Rief, W., Avorn, J., & Barsky, A. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.2.155 · Cited by 167 · see citing works
An assessment by the Statin Intolerance Panel: 2014 update
Guyton, J. R., Bays, H. E., Grundy, S. M., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.03.002 · Cited by 165 · see citing works
Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis
Su, X., Zhang, L., Lv, J., Wang, J., Hou, W., Xie, X., & Zhang, H. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.01.016 · Cited by 164 · see citing works
Prentice, R. L., Langer, R. D., Stefanick, M. L., Howard, B. V., Pettinger, M. B., Anderson, G. L., Barad, D. H., Curb, J. D., Kotchen, J. M., Kuller, L. H., et al. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj079 · Cited by 160 · see citing works
Randomized Polypill Crossover Trial in People Aged 50 and Over
Wald, D. S., Morris, J. K., & Wald, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041297 · Cited by 159 · see citing works
Self-citationPrevalence of Musculoskeletal Pain and Statin Use
Buettner, C., Davis, R. B., Leveille, S. G., Mittleman, M. A., & Mukamal, K. J. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0636-7 · Cited by 158 · see citing works
Pooling Research Results: Benefits and Limitations of Meta-Analysis
Ioannidis, J. P. A., & Lau, J. (1999) · The Joint Commission Journal on Quality Improvement · doi:10.1016/s1070-3241(16)30460-6 · Cited by 157 · see citing works
Testing cognitive function in elderly populations: the PROSPER study
Houx, P. J. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.4.385 · Cited by 153 · see citing works
Cohen, J. D., Cziraky, M. J., Cai, Q., Wallace, A. E., Wasser, T., Crouse, J. R., & Jacobson, T. A. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.05.030 · Cited by 151 · see citing works
Petersen, L. K., Christensen, K., & Kragstrup, J. (2010) · Age and Ageing · doi:10.1093/ageing/afq129 · Cited by 148 · see citing works
Petretta, M., Costanzo, P., Perrone-Filardi, P., & Chiariello, M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.08.001 · Cited by 141 · see citing works
Blamoun, A. I., Batty, G. N., DeBari, V. A., Rashid, A., Sheikh, M., & Khan, M. A. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01731.x · Cited by 141 · see citing works
Tsang, R., Colley, L., & Lynd, L. D. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.08.005 · Cited by 139 · see citing works
Janda, S., Park, K., FitzGerald, J. M., Etminan, M., & Swiston, J. R. (2009) · CHEST Journal · doi:10.1378/chest.09-0194 · Cited by 134 · see citing works
Statin treatment and reduced risk of pneumonia in patients with diabetes
van de Garde, E. M. W., Hak, E., Souverein, P. C., Hoes, A. W., van den Bosch, J. M. M., & Leufkens, H. G. M. (2006) · Thorax · doi:10.1136/thx.2006.062885 · Cited by 132 · see citing works
Antioxidant vitamins intake and the risk of coronary heart disease: meta-analysis of cohort studies
Ye, Z., & Song, H. (2008) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3282f11f95 · Cited by 131 · see citing works
<i>N</i>-of-1 (Single-Patient) Trials for Statin-Related Myalgia
Joy, T. R., Monjed, A., Zou, G. Y., Hegele, R. A., McDonald, C. G., & Mahon, J. L. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1921 · Cited by 130 · see citing works
Statins and Musculoskeletal Conditions, Arthropathies, and Injuries
Mansi, I. A., Frei, C. R., Pugh, M. J., Makris, U. E., & Mortensen, E. M. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6184 · Cited by 129 · see citing works
Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms
Okuyama, H., Langsjoen, P. H., Hamazaki, T., Ogushi, Y., Hama, R., Kobayashi, T., & Uchino, H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1011125 · Cited by 127 · see citing works
Forest plots and the interpretation of subgroups
Cuzick, J. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61026-4 · Cited by 127 · see citing works
The knowledge system underpinning healthcare is not fit for purpose and must change
Roberts, I., Ker, K., Edwards, P. J., Beecher, D., Manno, D., & Sydenham, E. (2015) · BMJ · doi:10.1136/bmj.h2463 · Cited by 126 · see citing works
Self-citationThe nocebo effect in the context of statin intolerance
Tobert, J. A., & Newman, C. B. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.05.002 · Cited by 125 · see citing works
Flagged first, then by citations
4 of the 299 references couldn’t be matched to a known paper.
Research works printed but not linked: 10
- Pocock SJ. Clinical Trials. Chichester: John Wiley & Sons, 1983.
- Early Breast Cancer Trialists' Collaborative Group. Treatment of Early Breast Cancer, volume 1. Worldwide Evidence 1985-1990. Oxford: Oxford University Press, 1990.
- Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1997; 16: 1017-29.
- Clarke R, Halsey J, Lewington S, et al. Eff ects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specifi c mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010; 170: 1622-31. 134
- Faasse K, Petrie KJ. The nocebo eff ect: patient expectations and medication side eff ects. Postgrad Med 2013; 89: 540-46. 142
- Grimes DA, Schulz KF. Nonspecifi c side eff ects of oral contraceptives: nocebo or noise? Contraception 2011; 83: 5-9. 144
- Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecifi c medication side eff ects and the nocebo phenomenon. JAMA 2002; 287: 622-27. 145
- Moriarty P, Thompson PD, Cannon CP, et al. ODYSSEY ALTERNATIVE: Effi cacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defi ned by a placebo run-in and statin rechallenge arm. http://circ.ahajournals. org/content/130/23/2105.full#T116 (accessed Aug 22, 2016). 155
- Godlee F. Adverse eff ects of statins. BMJ 2014; 348: g3306. 245
- Catalyst ABC 2014. Heart of the Matter. The Cholesterol Myth: Dietary Villains and Cholesterol Drug War. http://about.abc.net.au/ press-releases/statement-from-abc-managing-director-on-catalyst- ruling/ (accessed Aug 22, 2016). 296 How Big Pharma greed is killing tens of thousands around the world: Patients are over-medicated and often given profi table drugs with 'little proven benefi ts,' leading doctors warn. MailOnline, February, 2016. http://www.dailymail.co.uk/health/article-3460321/ How-Big-Pharma-greed-killing-tens-thousands-world-Patients- medicated-given-profi table-drugs-little-proven-benefi ts-leading- doctors-warn.html (accessed Aug 22, 2016). 297 PCSK9 Forum. Why are new treatments needed? http://www. pcsk9forum.org/about-pcsk9/why-are-new-treatments-needed/ (accessed Aug 22, 2016). 298
Cited by
Sorted by citations
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works
Self-citationKDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530 · see citing works
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485 · see citing works
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185 · see citing works
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · see citing works
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works
Self-citationFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962 · see citing works
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473 · see citing works
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211 · see citing works
The changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873 · see citing works
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691 · see citing works
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751 · see citing works
Self-citation2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Lawton, J. S., Tamis‐Holland, J. E., Bangalore, S., Bates, E., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.006 · Cited by 1,651 · see citing works
Biomarker definitions and their applications
Califf, R. M. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370217750088 · Cited by 1,546 · see citing works
Facing up to the global challenges of ageing
Partridge, L., Deelen, J., & Slagboom, P. E. (2018) · Nature · doi:10.1038/s41586-018-0457-8 · Cited by 1,475 · see citing works
Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001038 · Cited by 1,328 · see citing works
Hankey, G. J. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30962-x · Cited by 1,248 · see citing works
Effects of stress on the development and progression of cardiovascular disease
Kivimäki, M., & Steptoe, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.189 · Cited by 1,197 · see citing works
Reducing the Global Burden of Cardiovascular Disease, Part 1
Joseph, P. G., Leong, D. P., McKee, M., Anand, S. S., Schwalm, J.-D., Teo, K. K., Mente, A., & Yusuf, S. (2017) · Circulation Research · doi:10.1161/circresaha.117.308903 · Cited by 1,089 · see citing works
Self-citationEffects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047 · see citing works
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C. T., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S. D., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 920 · see citing works
Self-citationRichardson, T. G., Sanderson, E., Palmer, T. M., Ala-Korpela, M., Ference, B. A., Davey Smith, G., & Holmes, M. V. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003062 · Cited by 843 · see citing works
Self-citationArmitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31942-1 · Cited by 801 · see citing works
Self-citationBonaca, M. P., Nault, P., Giugliano, R. P., Keech, A. C., Pineda, A. L., Kanevsky, E., Kuder, J., Murphy, S. A., Jukema, J. W., Lewis, B. S., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032235 · Cited by 766 · see citing works
Self-citationWard, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 772 · see citing works
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 761 · see citing works
Self-citationIntracerebral haemorrhage: current approaches to acute management
Cordonnier, C., Demchuk, A. M., Ziai, W., & Anderson, C. S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31878-6 · Cited by 726 · see citing works
Atherosclerosis and inflammation: overview and updates
Geovanini, G. R., & Libby, P. (2018) · Clinical Science · doi:10.1042/cs20180306 · Cited by 703 · see citing works
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679 · see citing works
Self-citationCardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701488 · Cited by 624 · see citing works
Self-citationGenetic drug target validation using Mendelian randomisation
Schmidt, A. F., Finan, C., Gordillo‐Marañón, M., Asselbergs, F. W., Freitag, D. F., Patel, R. S., Tyl, B., Chopade, S., Faraway, R., Zwierzyna, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16969-0 · Cited by 564 · see citing works
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
Amarenco, P., Js, K., Labreuche, J., Charles, H., Abtan, J., Béjot, Y., Cabrejo, L., Jk, C., Ducrocq, G., Giroud, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910355 · Cited by 572 · see citing works
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 565 · see citing works
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544 · see citing works
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538 · see citing works
Nordanstig, J., Behrendt, C., Baumgärtner, I., Belch, J. J. F., Bäck, M., Fitridge, R., Hinchliffe, R. J., Lejay, A., Mills, J. L., Rother, U., et al. (2023) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.08.067 · Cited by 545 · see citing works
Impact of Lipids on Cardiovascular Health
Ference, B. A., Graham, I., Tokgozoglu, L., & Catapano, A. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.046 · Cited by 511 · see citing works
Lindahl, B., Baron, T., Erlinge, D., Hadziosmanovic, N., Nordenskjöld, A. E., Gard, A., & Jernberg, T. (2017) · Circulation · doi:10.1161/circulationaha.116.026336 · Cited by 490 · see citing works
The Magic of Randomization versus the Myth of Real-World Evidence
Collins, R., Bowman, L. J., Landray, M., & Peto, R. (2020) · New England Journal of Medicine · doi:10.1056/nejmsb1901642 · Cited by 480 · see citing works
Self-citationPrimary prevention of cardiovascular disease: A review of contemporary guidance and literature
Stewart, J., Manmathan, G. P. R., & Wilkinson, P. (2017) · JRSM Cardiovascular Disease · doi:10.1177/2048004016687211 · Cited by 477 · see citing works
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., de Oliveira, G. M. M., Simão, A. F. L., Dutra, Ó. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R., Giuliano, I. D. C. B., Filho, A. C. D. A., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 469 · see citing works
Köhler‐Forsberg, O., N. Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13016 · Cited by 432 · see citing works
Safety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424 · see citing works
Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
O’Donoghue, M. L., Giugliano, R. P., Wiviott, S. D., Atar, D., Keech, A., Kuder, J. F., Im, K., Murphy, S. A., Flores-Arredondo, J. H., López, J. A. G., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.061620 · Cited by 410 · see citing works
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370 · see citing works
Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage
Diener, H., & Hankey, G. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.072 · Cited by 376 · see citing works
PCSK9 inhibitors: clinical evidence and implementation
Sabatine, M. S. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 363 · see citing works
Mechanisms, Consequences, and Prevention of Coronary Graft Failure
Gaudino, M. F. L., Antoniades, C. A., Benedetto, U., Deb, S., Franco, A. D., Giammarco, G. D., Fremes, S. E., Glineur, D., Grau, J. B., He, G., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027597 · Cited by 357 · see citing works
Gupta, A., Thompson, D., Whitehouse, A., Collier, T., Dahlof, B., Poulter, N., Collins, R., & Sever, P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31075-9 · Cited by 343 · see citing works
Self-citationCoronary Artery Disease in Patients ≥80 Years of Age
Madhavan, M. V., Gersh, B. J., Alexander, K. P., Granger, C. B., & Stone, G. W. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.068 · Cited by 322 · see citing works
on behalf of the China Kadoorie Biobank Collaborative Group, Sun, L., Clarke, R., Bennett, D., Yu, C., Walters, R. G., Hill, M., Parish, S., Millwood, I. Y., Bian, Z., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0366-x · Cited by 316 · see citing works
Self-citationGencer, B., Marston, N. A., Im, K., Cannon, C. P., Sever, P., Keech, A., Braunwald, E., Giugliano, R. P., & Sabatine, M. S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32332-1 · Cited by 318 · see citing works
Self-citationAutier, P., Mullie, P., Macacu, A., Dragomir, M., Boniol, M., Coppens, K., Pizot, C., & Boniol, M. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30357-1 · Cited by 315 · see citing works
Brunner, F. J., Waldeyer, C., Ojeda, F., Salomaa, V. V., Kee, F., Sans, S., Thorand, B., Giampaoli, S., Brambilla, P., Tunstall‐Pedoe, H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32519-x · Cited by 308 · see citing works
Richardson, T. G., Leyden, G. M., Wang, Q., Bell, J. A., Elsworth, B., Davey Smith, G., & Holmes, M. V. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001547 · Cited by 304 · see citing works
Self-citation2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304 · see citing works
Self-citationCardiomyopathy in obesity, insulin resistance and diabetes
Nakamura, M., & Sadoshima, J. (2019) · The Journal of Physiology · doi:10.1113/jp276747 · Cited by 287 · see citing works
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 275 · see citing works
Reith, C. A., Baigent, C., Blackwell, L. S., Emberson, J., Spata, E., Davies, K., Halls, H. J., Holland, L., Wilson, K., Armitage, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01545-8 · Cited by 288 · see citing works
Self-citationThe Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264 · see citing works
Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications
Le Bastard, Q., Al‐Ghalith, G. A., Grégoire, M., Chapelet, G., Javaudin, F., Dailly, E., Batard, E., Knights, D., & Montassier, E. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14451 · Cited by 263 · see citing works
Sabatine, M. S., De Ferrari, G. M., Giugliano, R. P., Huber, K., Lewis, B. S., Ferreira, J., Kuder, J. F., Murphy, S. A., Wiviott, S. D., Kurtz, C. E., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034309 · Cited by 255 · see citing works
Self-citationCai, T., Abel, L., Langford, O., Monaghan, G., Aronson, J. K., Stevens, R., Lay-Flurrie, S. L., Koshiaris, C., McManus, R. J., Hobbs, R. F., et al. (2021) · BMJ · doi:10.1136/bmj.n1537 · Cited by 233 · see citing works
Disorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 260 · see citing works
Walker, V. M., Smith, G. D., Davies, N. M., & Martin, R. M. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx207 · Cited by 220 · see citing works
Self-citation2024 Clinical practice guidelines for Hypertension in adults
Кобалава, Ж. Д., Конради, А. О., Nedogoda, S. V., Shlyakhto, E. V., Arutyunov, G. P., Баранова, Е. И., Барбараш, О. Л., Bobkova, N. V., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6117 · Cited by 260 · see citing works
Reverse Causality in Cardiovascular Epidemiological Research: More Common Than Imagined?
Sattar, N., & Preiss, D. (2017) · Circulation · doi:10.1161/circulationaha.117.028307 · Cited by 211 · see citing works
Self-citationSabatine, M. S., Wiviott, S. D., Im, K., Murphy, S. A., & Giugliano, R. P. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2258 · Cited by 206 · see citing works
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub2 · Cited by 202 · see citing works
Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
Newman, J. D., Schwartzbard, A. Z., Weintraub, H. S., Goldberg, I. J., & Berger, J. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.001 · Cited by 205 · see citing works
Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx549 · Cited by 200 · see citing works
Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations
Selva-O’Callaghan, A., Alvarado-Cárdenas, M., Pinal‐Fernandez, I., Araguás, E. T., Milisenda, J. C., Martínez, M. Á., Marín, A., Labrador‐Horrillo, M., Juárez, C., & Grau‐Junyent, J. M. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1440206 · Cited by 202 · see citing works
Turner, R. M., & Pirmohamed, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010022 · Cited by 201 · see citing works
Ruscica, M., Ferri, N., Banach, M., Sirtori, C. R., & Corsini, A. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac020 · Cited by 209 · see citing works
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195 · see citing works
Sex- and Gender-Based Pharmacological Response to Drugs
Mauvais‐Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., Gouni‐Berthold, I., Heiman, M. L., Kautzky‐Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 194 · see citing works
Optimizing cholesterol treatment in patients with muscle complaints
Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.752 · Cited by 193 · see citing works
Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials
Herrett, E., Williamson, E., Brack, K., Beaumont, D., Perkins, A., Thayne, A., Shakur-Still, H., Roberts, I., Prowse, D., Goldacre, B., et al. (2021) · BMJ · doi:10.1136/bmj.n135 · Cited by 191 · see citing works
Self-citationTong, T. Y. N., Appleby, P. N., Bradbury, K. E., Perez‐Cornago, A., Travis, R. C., Clarke, R., & Key, T. J. (2019) · BMJ · doi:10.1136/bmj.l4897 · Cited by 194 · see citing works
Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis
Noubiap, J. J., Bigna, J. J., Nansseu, J. R., Nyaga, U. F., Balti, E. V., Echouffo-Tcheugui, J. B., & Kengne, A. P. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30275-4 · Cited by 187 · see citing works
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184 · see citing works
Self-citationPinal‐Fernandez, I., Casal-Domínguez, M., & Mammen, A. L. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.030 · Cited by 185 · see citing works
The LDL cumulative exposure hypothesis: evidence and practical applications
Ference, B. A., D, E. B. M., & Catapano, A. L. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01039-5 · Cited by 191 · see citing works
Mendelian randomisation in cardiovascular research: an introduction for clinicians
Bennett, D., & Holmes, M. V. (2017) · Heart · doi:10.1136/heartjnl-2016-310605 · Cited by 180 · see citing works
Yebyo, H. G., Aschmann, H. E., Kaufmann, M., & Puhan, M. A. (2019) · American Heart Journal · doi:10.1016/j.ahj.2018.12.007 · Cited by 178 · see citing works
Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults
Han, B. H., Sutin, D. G., Williamson, J. D., Davis, B. R., Piller, L. B., Pervin, H., Pressel, S., & Blaum, C. S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1442 · Cited by 178 · see citing works
Nussbaumerová, B., & Rosolová, H. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01167-2 · Cited by 185 · see citing works
Guaraldi, G., Malagoli, A., Calcagno, A., Mussi, C., Celesia, B. M., Carli, F., Piconi, S., Socio, G. V. D., Cattelan, A. M., Orofino, G., et al. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0789-0 · Cited by 179 · see citing works
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 180 · see citing works
Lerman, J. B., Joshi, A. A., Chaturvedi, A., Aberra, T. M., Dey, A. K., Rodante, J. A., Salahuddin, T., Chung, J. H. N., Rana, A., Teague, H., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.026859 · Cited by 186 · see citing works
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
Casula, M., Mozzanica, F., Scotti, L., Tragni, E., Pirillo, A., Corrao, G., & Catapano, A. L. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.03.001 · Cited by 175 · see citing works
Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States
Peters, S. A. E., Colantonio, L. D., Zhao, H., Bittner, V., Dai, Y., Farkouh, M. E., Monda, K. L., Safford, M. M., Muntner, P., & Woodward, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.032 · Cited by 173 · see citing works
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171 · see citing works
Inflammation as a Therapeutic Target in Atherosclerosis
Nguyen, M. T., Fernando, S., Schwarz, N., Tan, J. T. M., Bursill, C. A., & Psaltis, P. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081109 · Cited by 171 · see citing works
Unveiling the Role of Inflammation and Oxidative Stress on Age-Related Cardiovascular Diseases
de Almeida, A. J. P. O., Rezende, M. S. D. A., Dantas, S. H., Silva, S. D. L., de Oliveira, J. C. P. L., de Azevedo, F. D. L. A. A., Alves, R. M. F. R., de Menezes, G. M. S., dos Santos, P. F., Gonçalves, T. A. F., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1954398 · Cited by 167 · see citing works
Pennells, L. A. M., Kaptoge, S. K., Wood, A., Sweeting, M., Zhao, X., White, I. R., Burgess, S., Willeit, P., Bolton, T. R., Moons, K. G. M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy653 · Cited by 166 · see citing works
Self-citationIntegrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction
Riveros-Mckay, F., Weale, M. E., Moore, R., Selzam, S., Krapohl, E. M. L., Sivley, R. M., Tarran, W. A., Sørensen, P. B., Lachapelle, A. S., Griffiths, J. A., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003304 · Cited by 159 · see citing works
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164 · see citing works
Prabhakaran, D., Anand, S., Watkins, D., Gaziano, T., Wu, Y., Mbanya, J. C., Nugent, R., Ajay, V. S., Afshin, A., Adler, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32471-6 · Cited by 162 · see citing works
Self-citationFerence, B. A., Cannon, C. P., Landmesser, U., Lüscher, T. F., Catapano, A. L., & Ray, K. K. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx450 · Cited by 161 · see citing works
- Authors
- Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., Evans, S., Law, M., MacMahon, S., Martin, S., Neal, B., Poulter, N., Preiss, D., Ridker, P., Roberts, I., Rodgers, A., Sandercock, P., Schulz, K., Sever, P., Simes, J., Smeeth, L., Wald, N., Yusuf, S., & Peto, R.
- Affiliations
- University of Oxford (GB)
- Johns Hopkins University (US)
- University of Cambridge (GB)
- University of Bristol (GB)
- University of Wisconsin–Madison (US)
- University of London (GB)
- The University of Sydney (AU)
- Imperial College London (GB)
- Brigham and Women's Hospital (US)
- University of Edinburgh (GB)
- University of North Carolina at Chapel Hill (US)
- Population Health Research Institute (CA)
- Corresponding author
- Collins, Rory
- ORCID
- Collins, Rory
- Reith, Christina
- Emberson, Jonathan
- Armitage, Jane
- Baigent, Colin
- Blumenthal, Roger
- Danesh, John
- Smith, George Davey
- DeMets, David
- Evans, Stephen
- MacMahon, Stephen
- Martin, Seth
- Neal, Bruce
- Poulter, Neil
- Preiss, David
- Ridker, Paul
- Roberts, Ian
- Rodgers, Anthony
- Sandercock, Peter
- Schulz, Kenneth
- Smeeth, Liam
- Wald, Nicholas
- Yusuf, Salim
- Peto, Richard
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 388
- Issue
- 10059
- Pages
- 2532-2561
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2519634482
- Cited by
- 1,857
- References
- 299
- Citations by year
- 2026: 136 · 2025: 136 · 2024: 150 · 2023: 166 · 2022: 187 · 2021: 229 · 2020: 192 · 2019: 218 · 2018: 206 · 2017: 202 · 2016: 31
- FWCI
- 43.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc-nd)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- Cancer Research UK (16896)
- National Institute for Health and Care Research (NF-SI-0611-10057, HTA/14/49/159, 14/49/159, NF-SI-0513-10059)
- British Heart Foundation (SP/08/010/25939, SP/14/3/31114, RG/13/13/30194)
- Medical Research Council (MR/K006584/1, MR/L003120/1)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- statin therapy, LDL cholesterol lowering, cardiovascular disease prevention, secondary prevention, primary prevention, absolute risk reduction, statin adverse effects, myopathy, rhabdomyolysis, new-onset diabetes, hemorrhagic stroke, atorvastatin, long-term treatment, evidence evaluation, cardiovascular risk assessment, cost-effectiveness, randomized controlled trials, meta-analysis
- MeSH terms
- Anticholesteremic Agents, Clinical Trials as Topic, Coronary Disease, Humans, Cholesterol, LDL, Myocardial Infarction, Safety, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
